Vaccitech plc (VACC)

Overview

Barinthus Biotherapeutics plc represents a forefront entity in the domain of biopharmaceuticals, concentrating on the advancement of innovative T cell immunotherapeutic solutions aimed at empowering the immune system to conquer challenges such as chronic infectious diseases, autoimmunity, and cancer. Initially established under the name Vaccitech plc in 2016, the company underwent a rebranding to Barinthus Biotherapeutics plc in November 2023, showcasing its evolving focus and expanding portfolio in immunotherapy. Positioned in Didcot, United Kingdom, the company epitomizes clinical-stage research and development prowess, forging partnerships and licensing agreements with esteemed organizations like OUI, NIH, IMC, CanSino, CRUK, VOLT, and Arbutus to enhance and expedite its path to delivering groundbreaking treatments.

Products and Services

• VTP-300: This innovative immunotherapeutic candidate is currently under phase 2 studies. It is being explored as a possible element of a functional cure for patients with chronic hepatitis B virus (HBV) infection, indicating a significant step forward in treating this global health concern.
• VTP-200: Designed as a non-surgical product candidate, VTP-200 is undergoing phase 2 studies for the treatment of persistent high-risk human papillomavirus (HPV) infection. This approach represents an important innovation in managing HPV-related health issues.
• VTP-1000: A preclinical autoimmune candidate, VTP-1000 is tailored to treat patients with celiac disease, showcasing the company's commitment to tackling autoimmune disorders through advanced immunotherapeutic strategies.
• VTP-1100: Targeting HPV16+ cancers, this product candidate is part of Barinthus Biotherapeutics' broader initiative to address cancer via specific and targeted immunotherapy approaches.
• VTP-850/850: As a second-generation immunotherapeutic under phase 2 studies, it aims to treat recurrent prostate cancer, reflecting the company's dedication to confronting cancer with cutting-edge immunotherapeutic solutions.
• AB-729-202: Partnered for development, this candidate is currently under phase 2a studies for treating patients with chronic HBV infection, demonstrating Barinthus Biotherapeutics' collaborative efforts to enhance treatment paradigms for HBV.
• VTP-600: An immunotherapy candidate undergoing phase 1 studies, VTP-600 is being evaluated as a potential treatment for NSCLC in combination with standard of care treatments, highlighting the company's innovative approach to cancer therapy.
• VTP-500: This prophylactic vaccine candidate is under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus, exemplifying the company's proactive measures against viral threats.
• VTP-400: Aimed at preventing shingles in adults aged 50 years and older, VTP-400 is under phase 1 studies. This prophylactic vaccine candidate underscores Barinthus Biotherapeutics’ commitment to improving adult health through vaccination.
• Vaxzevria (formerly VTP-900 and AZD1222): This prophylactic vaccine has been developed for the prevention of COVID-19 infection, marking a significant contribution to the global efforts in combating the pandemic.